You may be able to take part if you are:
- Aged 55-85
- Have a diagnosis of Mild cognitive impairment or mild dementia due to Alzheimer’s disease
- Have a study partner who is willing to take part in the study with you
The purpose of these 3-year studies is to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer’s disease.
This will be done by comparing semaglutide against placebo on the effect on cognition and daily functioning. Semaglutide is already used to treat people with type 2 diabetes.
You may be able to take part if you are:
The study will be explained fully to you and your partner, it includes:
* You will have the opportunity to discuss the results of these scans with your study doctor before taking any medication.